MA23961A1 - Benzylaminopiperidines substituees et compositions les contenant - Google Patents

Benzylaminopiperidines substituees et compositions les contenant

Info

Publication number
MA23961A1
MA23961A1 MA24339A MA24339A MA23961A1 MA 23961 A1 MA23961 A1 MA 23961A1 MA 24339 A MA24339 A MA 24339A MA 24339 A MA24339 A MA 24339A MA 23961 A1 MA23961 A1 MA 23961A1
Authority
MA
Morocco
Prior art keywords
benzylaminopiperidines
substituted
compositions containing
compositions
substituted benzylaminopiperidines
Prior art date
Application number
MA24339A
Other languages
English (en)
Inventor
Stake Kunio
Shishido Yuji
Wakabayashi Hiroaki
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA23961A1 publication Critical patent/MA23961A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA24339A 1995-08-24 1996-08-23 Benzylaminopiperidines substituees et compositions les contenant MA23961A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24

Publications (1)

Publication Number Publication Date
MA23961A1 true MA23961A1 (fr) 1997-04-01

Family

ID=11004362

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24339A MA23961A1 (fr) 1995-08-24 1996-08-23 Benzylaminopiperidines substituees et compositions les contenant

Country Status (42)

Country Link
US (1) US6506775B1 (fr)
EP (2) EP0861235B1 (fr)
JP (1) JP3084069B2 (fr)
KR (1) KR100288673B1 (fr)
CN (1) CN1153764C (fr)
AP (1) AP643A (fr)
AR (1) AR006305A1 (fr)
AT (2) ATE208377T1 (fr)
AU (1) AU702698B2 (fr)
BG (1) BG64126B1 (fr)
BR (1) BR9609989A (fr)
CA (1) CA2227814C (fr)
CO (1) CO4480738A1 (fr)
CZ (1) CZ297543B6 (fr)
DE (2) DE69631390T2 (fr)
DK (2) DK1114817T3 (fr)
DZ (1) DZ2086A1 (fr)
ES (2) ES2211684T3 (fr)
HK (1) HK1014935A1 (fr)
HR (1) HRP960386B1 (fr)
HU (1) HU225480B1 (fr)
IL (1) IL119078A (fr)
IS (1) IS1947B (fr)
MA (1) MA23961A1 (fr)
MX (1) MX9801467A (fr)
MY (1) MY114800A (fr)
NO (1) NO310720B1 (fr)
NZ (1) NZ308207A (fr)
OA (1) OA10666A (fr)
PE (2) PE20010700A1 (fr)
PL (1) PL186773B1 (fr)
PT (2) PT861235E (fr)
RO (1) RO119299B1 (fr)
RU (1) RU2152930C2 (fr)
SI (2) SI1114817T1 (fr)
SK (1) SK282925B6 (fr)
TN (1) TNSN96107A1 (fr)
TR (1) TR199800300T1 (fr)
TW (1) TW340842B (fr)
UA (1) UA48981C2 (fr)
WO (1) WO1997008144A1 (fr)
YU (1) YU49122B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
GEP20043224B (en) * 1999-05-06 2004-04-26 Pfizer Prod Inc Substituted Benzolactam Compounds
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
EP1178984B1 (fr) * 1999-05-21 2003-03-19 Pfizer Products Inc. Derives 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchromane
CA2324116A1 (fr) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Antagonistes du recepteur nk-1 et eletriptan pour le traitement de la migraine
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (fr) * 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
WO2005113503A2 (fr) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites de (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (fr) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
WO2009111354A2 (fr) 2008-03-03 2009-09-11 Tiger Pharmatech Inhibiteurs de la tyrosine kinase
JP5511080B2 (ja) 2008-03-31 2014-06-04 興和株式会社 １，３−ジヒドロイソベンゾフラン誘導体
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
ES2528404T3 (es) 2009-05-12 2015-02-10 Bristol-Myers Squibb Company Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
AU2010247849B2 (en) 2009-05-12 2015-11-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
WO2012027236A1 (fr) 2010-08-23 2012-03-01 Schering Corporation Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (fr) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Inhibition facilitée par l'interférence d'arn de l'expression d'un gène au moyen d'acides nucléiques interférents courts (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012145471A1 (fr) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2900241B1 (fr) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
EP3706742B1 (fr) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668A4 (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
JPH0794440B2 (ja) * 1991-03-26 1995-10-11 フアイザー・インコーポレイテツド 置換ピペリジンの立体選択的製造
DE9290083U1 (de) * 1991-06-20 1994-02-17 Pfizer Inc., New York, N.Y. Fluoralkoxybenzylamino-Derivate von stickstoffhaltigen Heterocyclen
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (fr) * 1993-11-17 1995-10-11 Pfizer Antagonistes de la substance P pour le traitement et la prévention de l'erythème solaire.
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
PT780375E (pt) * 1995-12-21 2002-12-31 Pfizer 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
HUP9901159A3 (en) 2000-05-29
DZ2086A1 (fr) 2002-07-22
IL119078A (en) 2003-11-23
ES2163017T3 (es) 2002-01-16
DK0861235T3 (da) 2001-12-27
KR100288673B1 (ko) 2001-05-02
US6506775B1 (en) 2003-01-14
EP0861235B1 (fr) 2001-11-07
CN1193961A (zh) 1998-09-23
SI1114817T1 (en) 2004-06-30
YU49122B (sh) 2004-03-12
DE69616817T2 (de) 2002-04-04
PT861235E (pt) 2002-03-28
ATE208377T1 (de) 2001-11-15
AP643A (en) 1998-04-24
NO980751D0 (no) 1998-02-23
MX9801467A (es) 1998-05-31
HUP9901159A2 (hu) 1999-07-28
CO4480738A1 (es) 1997-07-09
CZ52198A3 (cs) 1999-01-13
TW340842B (en) 1998-09-21
BG64126B1 (bg) 2004-01-30
BG102288A (en) 1998-09-30
CZ297543B6 (cs) 2007-02-07
DE69616817D1 (de) 2001-12-13
SI0861235T1 (en) 2002-04-30
YU47896A (sh) 1998-12-23
HRP960386B1 (en) 2002-04-30
WO1997008144A1 (fr) 1997-03-06
DE69631390T2 (de) 2004-11-25
KR19990044077A (ko) 1999-06-25
NO310720B1 (no) 2001-08-20
IS4644A (is) 1997-12-30
CA2227814C (fr) 2002-12-31
NZ308207A (en) 1998-07-28
HRP960386A2 (en) 1998-04-30
PE1398A1 (es) 1998-02-27
EP1114817B1 (fr) 2004-01-21
RU2152930C2 (ru) 2000-07-20
AR006305A1 (es) 1999-08-25
EP0861235A1 (fr) 1998-09-02
ATE258166T1 (de) 2004-02-15
RO119299B1 (ro) 2004-07-30
PE20010700A1 (es) 2001-07-09
PL325332A1 (en) 1998-07-20
TNSN96107A1 (fr) 2005-03-15
BR9609989A (pt) 1999-07-06
CA2227814A1 (fr) 1997-03-06
HK1014935A1 (en) 1999-10-08
EP1114817A1 (fr) 2001-07-11
ES2211684T3 (es) 2004-07-16
SK20798A3 (en) 1999-03-12
SK282925B6 (sk) 2003-01-09
PL186773B1 (pl) 2004-02-27
MY114800A (en) 2003-01-31
IS1947B (is) 2004-10-13
JP3084069B2 (ja) 2000-09-04
DK1114817T3 (da) 2004-04-26
AU5776996A (en) 1997-03-19
UA48981C2 (uk) 2002-09-16
CN1153764C (zh) 2004-06-16
IL119078A0 (en) 1996-11-14
JPH10510554A (ja) 1998-10-13
PT1114817E (pt) 2004-05-31
DE69631390D1 (de) 2004-02-26
HU225480B1 (en) 2006-12-28
OA10666A (en) 2002-11-25
NO980751L (no) 1998-02-23
AP9600850A0 (en) 1996-10-31
TR199800300T1 (xx) 1998-06-22
AU702698B2 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
MA23961A1 (fr) Benzylaminopiperidines substituees et compositions les contenant
MA23895A1 (fr) Amides therapeutiques et compositions les contenant
DZ2361A1 (fr) Dérivés de 6-phénylpyridyl-2-amine et compositionspharmaceutiques les contenant
CY2005007I1 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
MA24466A1 (fr) Compositions contenant de la tetrahydrolistatine
DE69631056D1 (de) Zusammensetzungen von süssigkeiten
DE69632129D1 (de) Diol enthaltende zusammensetzungen
FR2740682B1 (fr) Composition topique contenant de la capsazepine
MA26553A1 (fr) Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
BR9607058A (pt) Composição
BR9606809A (pt) Composição inseticidamente ativa
DE69620642D1 (de) Reiningungsverfahren und-zusammensetzung
PT728814E (pt) Composicao betuminosa
BR9609903A (pt) ComposiçÃo inseticidamente ativa
FR2732019B1 (fr) Spiropyrannes photochromiques, compositions et articles les contenant
DE69616374D1 (de) Germizide zusammensetzung
DE69605016D1 (de) Intumeszenzzusammensetzung
FR2751648B1 (fr) Naphtopyranes photochromiques, compositions et articles les contenant
FR2739382B1 (fr) Fraction ribosomale et composition la contenant
DE69603228D1 (de) Aluminoxanate-Zusammensetzungen
ATE206150T1 (de) Farbstoffstabilisierte zusammensetzungen
BR9607946A (pt) Composição
BR9603032A (pt) Composição pesticida
FR2723377B1 (fr) Compositions nettoyantes ou decapantes, et preparations les contenant
FR2738248B1 (fr) Spiroxazines photochromiques, compositions et articles les contenant